SSI

December 29, 2015December 29, 2015

Clinical Trials Underway into Immunotherapies for Crohn’s Disease and Ulcerative Colitis

News

Qu Biologics Inc. recently provided an update for ongoing clinical trials assessing the company’s lead candidate for inflammatory bowel diseases (IBD), namely ulcerative colitis and Crohn’s disease. The company also announced it has ... Read more

April 3, 2015April 3, 2015

Qu Biologics Granted US Patent For Use Of E. Coli To Treat Crohn’s Disease

IBD News, News

Qu Biologics Inc., a biotechnology firm currently developing Site Specific Immunomodulators (SSIs) to restore regular immune function in a specific targeted diseased organ, recently announced that the United States Patent and Trademark Office issued a U.S. ... Read more

October 30, 2014October 30, 2014

Qu Biologics Cleared to Proceed with Crohn’s Disease Clinical Trial, DSMC Says

Crohn's Disease, News

Qu Biologics, Inc., a biotech company that specializes in formulating Site Specific Immunomodulators (SSI) for the restoration of normal immune system function, has just announced that a Data Safety Monitoring Committee ... Read more